• Explore /
  • Poster
  • / A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

Abstract Poster

Authors

David S. Hong

David S. Hong

The University of Texas MD Anderson Cancer Center, Houston, TX

David S. Hong , Kathleen N. Moore , Johanna C. Bendell , Daniel D. Karp , Judy Sing-Zan Wang , Susanna Varkey Ulahannan , Melissa Lynne Johnson , Raid Aljumaily , Scott Hynes , Sophie Callies , Rodney Decker , Elizabeth LaBell , Michele Niland , Xuejing Aimee Wang , Aimee Bence Lin , Manish R. Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT02124148

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3091)

DOI

10.1200/JCO.2019.37.15_suppl.3091

Abstract #

3091

Poster Bd #

83

Abstract Disclosures

Similar Posters

First Author: Sarina A. Piha-Paul

First Author: Kathleen N. Moore

First Author: Katherine M. Bell-McGuinn

First Author: Cristina Saura